HC Wainwright Issues Pessimistic Forecast for ACTU Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Equities research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Actuate Therapeutics in a research note issued to investors on Monday, May 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.20) for the quarter, down from their prior forecast of ($0.17). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Actuate Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at ($0.75) EPS and FY2029 earnings at ($0.07) EPS.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01).

Several other brokerages have also weighed in on ACTU. Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.50.

Actuate Therapeutics Price Performance

ACTU stock opened at $2.40 on Wednesday. Actuate Therapeutics has a 1 year low of $1.58 and a 1 year high of $11.99. The firm has a market capitalization of $57.43 million, a P/E ratio of -2.47 and a beta of 0.92. The business’s 50-day moving average is $2.54 and its two-hundred day moving average is $4.59.

Hedge Funds Weigh In On Actuate Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Voss Capital LP increased its stake in Actuate Therapeutics by 213.2% in the third quarter. Voss Capital LP now owns 896,278 shares of the company’s stock valued at $5,996,000 after purchasing an additional 610,138 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Actuate Therapeutics during the fourth quarter valued at about $579,000. BIOS Capital Management LP boosted its position in shares of Actuate Therapeutics by 0.9% in the third quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock worth $67,234,000 after buying an additional 84,917 shares during the period. Geode Capital Management LLC boosted its position in shares of Actuate Therapeutics by 252.5% in the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock worth $721,000 after buying an additional 84,561 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Actuate Therapeutics by 19.5% in the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock worth $2,114,000 after buying an additional 51,546 shares during the period.

Trending Headlines about Actuate Therapeutics

Here are the key news stories impacting Actuate Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Actuate Therapeutics and maintained a $15.00 price target, implying substantial upside from the current share price. Benzinga article
• Neutral Sentiment: The analyst still expects Actuate to post losses over the next several years, with projected EPS of $(0.84) in FY2026, $(0.71) in FY2027, and $(0.75) in FY2028, suggesting the company remains in an early development phase.
• Negative Sentiment: HC Wainwright lowered multiple earnings forecasts, including Q2 2026 to $(0.20) from $(0.17), Q3 2026 to $(0.21) from $(0.18), Q4 2026 to $(0.23) from $(0.19), and FY2029 to $(0.07) from $0.04, signaling a more cautious outlook.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.